731. Autologous Transplantation: Clinical and Epidemiological: Poster II

Salvage Transplant Versus CAR-T Cell Therapy for Relapsed Multiple Myeloma

Autologous HSCT for Multiple Sclerosis Should be Done Early in the Course of the Disease

Improving the Utilization and Tolerability of Thiotepa-Based Autologous Stem Cell Transplantation in Primary CNS Lymphoma

Gut Microbiome Faecalibacterium Abundance in Patients with Plasma Cell Disorders Undergoing Autologous Hematopoietic Stem Cell Transplant Is Associate

Age-Based Comparison of Stem Cell Transplantation during the First Line of Therapy for Multiple Myeloma Patients

Long-Term Remissions after First-Line Autologous Stem Cell Transplantation for Mantle Cell Lymphoma

Risk and Response Adapted Approach for Treatment of Myeloma: Pushing Autologous Transplant Down the Hierarchy

Co-Expression of C-MYC/BCL2 Is Associated with Inferior Survival Outcomes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Autologous Stem C

Engraftment Syndrome during Autologous Stem Cell Transplant in Hodgkin Lymphoma Patients Treated with Checkpoint Inhibitors: A Multi-Center Retrospect